You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

942 Results
Guidelines and Advice
Drug
Other Name(s): Sylvant®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Les programmes cliniques d’Action Cancer Ontario sont mis en œuvre en collaboration avec les cliniciens des Programmes régionaux de cancérologie en...
Document

Pages